Reference is made to the Company's announcement on 17 November 2016 regarding a underwritten rights issue proposed resolved at an extraordinary general meeting on 8 December 2016. The rights issue is subject to shareholder approval and a prospectus approved by the Norwegian Financial Supervisory Authority and published by the Company.
Key information in relation to the proposed rights issue:
Date on which the proposed terms and conditions of the rights issue were announced: 17 November 2016
Last day including right: 8 December 2016
Ex-date: 9 December 2016
Record date: 12 December 2016
Date of approval: Not yet approved. Proposed that the extraordinary general meeting to be held at 8 December 2016 approves the rights issue
Maximum number of new shares: 10,000,000 new shares
Subscription price per share: NOK 7
This information is published in accordance with the requirements of Continuing Obligations of stock exchange listed companies.
For more information visit: www.pcibiotech.com
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo
Per Walday, CEO, email@example.com, Mobile: +47 917 93 429
Last updated on: 18/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.